New compounds to treat tuberculosis
Official title: Development of 1,2,4-Triazolyl Compounds and their derivatives as a New Treatment for Tuberculosis
Funded at Washington University · NIH-10998882 · Data updated 2026-11-12
This study is exploring new medicines made from special compounds to help fight tuberculosis, especially the tough strains that don't respond to current treatments, so that patients can have better options for getting well.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $787,171 |
| NIH project number | 1R01AI181316-01A1 |
| Project ID | NIH-10998882 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those who have strains resistant to standard antibiotic treatments.
✕Less likely to help
Patients with non-tuberculosis infections or those who do not have a diagnosis of tuberculosis may not benefit from this research.
What this research studies
This research focuses on developing a new class of compounds, specifically nitro-containing 1,2,4-triazoles, to combat tuberculosis (TB), particularly drug-resistant strains. The researchers have identified these compounds as potent inhibitors of Mycobacterium tuberculosis, the bacteria responsible for TB, and are investigating their unique mechanisms of action. By understanding how these compounds work and their effectiveness against resistant strains, the research aims to provide new treatment options for patients with TB. The study includes laboratory experiments to test the compounds' efficacy and safety.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for tuberculosis, especially for patients with drug-resistant forms of the disease.
How similar studies have gone: Other research has shown promise in developing new antibiotics for tuberculosis, but the specific approach of using nitro-containing 1,2,4-triazoles is relatively novel.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Stallings, Christina Leigh — Washington University
- Study coordinator: Stallings, Christina Leigh
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.